Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00249-7/fulltext?dgcid=hubspot_email_infocusalerts-oncology_feature&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-8O3krwvyjioY6QorEwp1o6SCjjMHJDW7E74lqRPSZf_IeJL9U-E2db1g86NQEO4rLjXG1pYKo3u6Yxgnw_Cstypp4y8g&_hsmi=333150588&utm_content=332418629&utm_source=hs_email